Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
The U.S. Food and Drug Administration allowed Alnylam Pharmaceuticals Inc. to restart clinical trials on a drug to treat patients with a rare bleeding disorder.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
The new FDA-approved indications for Adynovate provide more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule.
After the announcement by Biogen that it was spinning off its hemophilia business, analysts and investors are pondering, somewhat quizzically, just what it means.
Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]
Baxalta’s effort to align its marketing to customer behavior has led the company into unmapped territory for a pharmaceutical company – Instagram.
The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand disease, which is caused by the deficiency or defect in von Willebrand factor, a protein that is critical for blood clotting. The disease affects about […]
Swiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma. A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]